Postexposure prophylaxis with nirmatrelvir-ritonavir does not cut COVID-19 Infection
Jul 18, 2024
No significant reduction was seen in the risk for symptomatic SARS-CoV-2 infection with postexposure prophylaxis for five or 10 days.
Hospital-onset SARS-CoV-2 infection during omicron linked to morbidity
Jul 15, 2024
Hospital-onset SARS-CoV-2 remained associated with increased morbidity and mortality during the omicron era.
COVID-19 tied to higher risk for new, worsening bladder symptoms
Nov 07, 2022
Symptomatic infection tied to three times greater risk for developing new or worsening overactive bladder symptoms
Food allergy tied to lower risk for SARS-CoV-2 infection
Jun 09, 2022
Asthma does not raise the risk for infection or household transmission.
Severe SARS-CoV-2 appears to infect coronary vessels
Oct 05, 2023
SARS-CoV-2 targets plaque macrophages, and its entry is increased in cholesterol-loaded primary macrophages.
Scientists report ‘rogue antibodies’ behind severe clotting with COVID-19
Feb 18, 2022
The study authors suggest that future research assess the potential benefits of screening COVID-19 patients for antiphospholipids and other autoantibodies.
Risk for diabetes after COVID-19 still increased during omicron phase
Feb 14, 2023
The risk for new-onset diabetes is significantly elevated during the omicron-dominant phase, but no increase was seen for risks for hypertension or hyperlipidemia.
Federal final rule drops bring cries of ‘flawed,’ ‘aggressive,’ ‘dramatic’ from senior living...
By
Kimberly Bonvissuto
Apr 25, 2024
Late April brought a shower of regulatory changes as the federal government dropped four major final rules this week that the senior living and care industry is calling “flawed,” “aggressive” and...
Neurological, neuropsychiatric symptoms common in COVID-19
Jun 10, 2021
Symptoms with the highest prevalence included anosmia, weakness, fatigue, dysgeusia, myalgia, and depression.
Biden makes national push for ‘long COVID’ research
Apr 06, 2022
Efforts will include speeding up the registrations of 40,000 people both with and without long COVID for a study on the condition.